====== Tramadol (Ultram®) ====== ^ Tramadol | {{ :neuro:opioids:tramadol_as_a_racemic_mixture.svg?200 |}} | | Brand Names | Ultram®, ConZip® | | Drug Class | [[neuro:opioids:start|Opioid]] (Weak μ-agonist, Dual Mechanism) | | Primary Indication | Moderate Pain | | Relative Potency | ~0.1× Morphine | | Mechanism | Weak μ agonist + SNRI | | Seizure Risk | Yes | | Serotonin Syndrome Risk | Yes | | Controlled Substance | Schedule IV | | FDA Approval | 1995 | ===== Overview ===== Tramadol is a centrally acting analgesic with a dual mechanism of action: * Weak μ-opioid receptor agonism * Inhibition of serotonin and norepinephrine reuptake It provides modest analgesia and carries unique risks not seen with traditional opioids, including seizures and serotonin syndrome. ---- ===== Mechanism of Action ===== **Receptor Activity** * Weak μ-opioid receptor agonist **Monoamine Effects** * Inhibits serotonin reuptake * Inhibits norepinephrine reuptake **Metabolism** * CYP2D6 converts tramadol → O-desmethyltramadol (active metabolite with stronger μ activity) Analgesic effect is partly dependent on CYP2D6 activity. ---- ===== Indications ===== * Moderate acute pain * Chronic musculoskeletal pain * Neuropathic pain (limited evidence) Not appropriate for severe pain requiring potent opioid therapy. ---- ===== Contraindications ===== Absolute: * Concomitant MAOI use * Severe respiratory depression * Acute intoxication with CNS depressants Relative / Caution: * Seizure disorders * Concurrent SSRI/SNRI use * Hepatic impairment * Renal impairment * CYP2D6 ultra-rapid metabolizers ---- ===== Dosing ===== Immediate-Release: * 50–100 mg every 4–6 hours Maximum: * 400 mg/day (lower in elderly) Renal impairment: * Dose adjustment required Extended-release: * Once daily dosing ---- ===== Pharmacokinetics ===== Absorption: * Oral Metabolism: * CYP2D6 → active metabolite * CYP3A4 involvement Half-life: * ~6 hours Elimination: * Renal CYP2D6 poor metabolizers → reduced analgesic effect CYP2D6 ultra-rapid metabolizers → increased toxicity risk ---- ===== Adverse Effects ===== Common: * Nausea * Dizziness * Sedation * Constipation Serious: * Seizures * Serotonin syndrome * Respiratory depression (less than full agonists) * Physical dependence Seizure risk increases with: * High doses * SSRIs/SNRIs * TCAs * Bupropion ---- ===== Drug Interactions ===== Increased serotonin syndrome risk: * SSRIs * SNRIs * MAOIs * Linezolid * St. John’s Wort CYP2D6 inhibitors (↓ analgesia): * Fluoxetine * Paroxetine CNS depressants: * Benzodiazepines * Alcohol ---- ===== Monitoring ===== Clinical: * Pain response * Sedation * Signs of serotonin toxicity High-risk patients: * History of seizures * Polypharmacy ---- ===== Clinical Pearls ===== * Weak μ agonist + SNRI mechanism. * Analgesia depends partly on CYP2D6 activation. * Higher seizure risk than other opioids. * Risk of serotonin syndrome with SSRIs/SNRIs. * Schedule IV (lower abuse potential than Schedule II opioids). * Not appropriate for severe acute pain. ---- ===== Toxicity ===== Overdose may present with: * CNS depression * Seizures * Serotonin syndrome * Respiratory depression Naloxone may reverse respiratory depression but does NOT treat seizures. See: * [[neuro:opioids:naloxone|Naloxone]] ---- ===== Comparison Within Class ===== Compared to [[neuro:opioids:morphine|Morphine]]: * Much weaker * Has serotonergic activity Compared to [[neuro:opioids:tapentadol|Tapentadol]]: * More serotonergic * Higher seizure risk Compared to [[neuro:opioids:codeine|Codeine]]: * Similar potency * More complex mechanism ---- ===== Related ===== * [[neuro:opioids:start|Opioids]] * [[neuro:opioids:tapentadol|Tapentadol]] * [[neuro:opioids:morphine|Morphine]] * [[neuro:opioids:naloxone|Naloxone]]